The natural history of multiple sclerosis
- PMID: 7739500
The natural history of multiple sclerosis
Abstract
The natural history of MS is highly variable. There is substantial heterogeneity in the clinical manifestations but, at this point, it is reasonable to consider all idiopathic inflammatory demyelinating diseases of the central nervous system as representing a spectrum of the same disease. In large populations, 20% to 40% have "benign disease," defined as having less than moderate disability after 10 years. Benign is a potentially misleading term because many of these patients subsequently will become disabled. Half will develop progressive MS within 10 years and will require some form of walking aid within 15 years following the onset of MS. Survival is not greatly shortened in mildly disabled patients, but the observed mortality is increased four-fold over the general population in patients with advanced disability. Patients with the greatest risk of disability are those with PP MS and RR patients who are older at onset, have pyramidal or cerebellar involvement at onset, and who have frequent or prolonged attacks with incomplete recovery. The biological basis for the variation in the course of MS is understood only in a very limited way. The short- and long-term course of MS may be determined by different biological variables. Short-term benefit in clinical trials should not be assumed to indicate long-term reduction in the risk of permanent disability.
Similar articles
-
[Course of illness and prognosis of multiple sclerosis. 1: The natural illness course].Nervenarzt. 1996 Jun;67(6):435-43. Nervenarzt. 1996. PMID: 8767197 Review. German.
-
The natural history of multiple sclerosis: update 1998.Semin Neurol. 1998;18(3):301-7. doi: 10.1055/s-2008-1040881. Semin Neurol. 1998. PMID: 9817534 Review.
-
[Benign forms of multiple sclerosis].Rev Prat. 1991 Sep 15;41(20):1904-7. Rev Prat. 1991. PMID: 1925374 Review. French.
-
Natural history of multiple sclerosis: a unifying concept.Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16. Brain. 2006. PMID: 16415308
-
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.Oncologist. 1996;1(5):326-330. Oncologist. 1996. PMID: 10388011
Cited by
-
Development of oral cladribine for the treatment of multiple sclerosis.J Neurol. 2010 Feb;257(2):163-70. doi: 10.1007/s00415-009-5359-0. J Neurol. 2010. PMID: 19921304 Review.
-
Quality of life in multiple sclerosis: translation in French Canadian of the MSQoL-54.Health Qual Life Outcomes. 2003 Nov 24;1:70. doi: 10.1186/1477-7525-1-70. Health Qual Life Outcomes. 2003. PMID: 14636427 Free PMC article.
-
Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis.Iran J Neurol. 2018 Jul 6;17(3):123-128. Iran J Neurol. 2018. PMID: 30886679 Free PMC article.
-
Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis.Ther Clin Risk Manag. 2014 Mar 27;10:229-39. doi: 10.2147/TCRM.S53285. eCollection 2014. Ther Clin Risk Manag. 2014. PMID: 24707183 Free PMC article. Review.
-
The search for a balance between short and long-term treatment outcomes in multiple sclerosis.J Neurol. 2008 Mar;255 Suppl 1:75-83. doi: 10.1007/s00415-008-1010-8. J Neurol. 2008. PMID: 18317679 Review.
Publication types
MeSH terms
LinkOut - more resources
Medical
Miscellaneous